Alexandra Gerlach, Senior Content Producer

Pelabresib is an investigational, oral, small molecule that inhibits bromodomain and extraterminal (BET) proteins.

The data support the use of supportive anemia care agents in combination with ruxolitinib (Jakafi; Incyte Corp).

Zenocutuzumab-zbco is a bispecific antibody that targets and binds to HER2 and HER3.

Metabolic bariatric surgery rates has decreased in response to increased use of glucagon-like peptide-1 (GLP-1) receptor agonists.

Anemia is a very common adverse effect associated with the use of ruxolitinib.

Postural orthostatic tachycardia syndrome (POTS) diagnoses have greatly increased following the COVID-19 pandemic.

E-cigarette manufacturers claim the products aid in smoking cessation for adults without the risk of adolescent usage.

The therapy has similar benefits for both older and younger patients with multiple myeloma.

Lipoprotein(a) is a known risk factor for atherosclerotic cardiovascular disease.

Anemia is a common adverse effect of ruxolitinib, calling for new approaches to mitigate risks.

The addition of navitoclax was associated with durable response and potential disease modification.

Methemoglobinemia is a blood disorder that affects proper release of oxygen around the body.

The proposed rule would increase access to semaglutide for millions of Americans.

Acoramidis is a novel, highly potent transthyretin stabilizer.

Belantamab mafodotin demonstrated benefits in overall survival in the phase 3 DREAMM-7 trial.

Rusfertide may sustain hematocrit levels in patients with polycythemia vera.

Harpreet Bhatia, MD, MAS, FACC, discusses emerging new approaches to lipid lowering therapies.

Abelacimab is an investigational, selective, fully human monoclonal antibody.

Rachel Chandra, PharmD, MPH, FASHP, shares insight into the VALOR-QI program.

Rachel Chandra, PharmD, MPH, FASHP shares methods for improving adherence to lipid lowering therapies discussed at the AHA 2024 Scientific Sessions.

Christian Ruff, MD, MPH shared the results of the AZALEA-TIMI 71 trial.

Leonard Egede, MD, MS, FACP discussed the association of historical redlining and contemporary structural racism on life expectancy.

Rebekah Walker, PhD raises awareness of the long-lasting health implications caused by historic redlining.

Milind Desai, MD, MBA shares insight into the REMS program for patients with obstructive hypertrophic cardiomyopathy.

Craig Beavers, PharmD, FACC, FAHA, FCCP, BCCP, CACP will be moderating a session about social determinants of health and heart failure.

These therapies represent an encouraging advancement in cardiovascular care.

According to the study, 20% of patients with myeloproliferative neoplasms progress to blast phase.

If accepted, daratumumab would be the first approved treatment for smoldering multiple myeloma.

Off-label semaglutide has been linked to serious adverse effects, calling for increased regulation around compounding.

The nomogram model demonstrated good predictive capabilities to assess progression risk to overt primary myelofibrosis.